News
Windward Bio catches $175m from its IPO

Windward Bio catches $175m from its IPO

Swiss biotech Windward Bio has raised $175m in its Nasdaq IPO as it prepares to take on some heavyweight rivals with its long-acting TSLP inhibitor.

News
A 3D bioprinter creates small, three-dimensional tumours in a collagen gel that continue to grow. The researchers then add T-cells and observe what happens.

3D-printed tumours could aid cancer therapy R&D

Researchers in the Netherlands have developed 3D-printed 'mini tumours' that behave like real cancerous tissue and can be used to test new treatments, including drug and cell-based immunoth

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

Patients

R&D

News
Windward Bio catches $175m from its IPO

Windward Bio catches $175m from its IPO

Swiss biotech Windward Bio has raised $175m in its Nasdaq IPO as it prepares to take on some heavyweight rivals with its long-acting TSLP inhibitor.

Partner Content

Partner Content
LEAP HR: Life Sciences Europe
Partner Content

LEAP HR: Life Sciences Europe

Europe’s Only Industry-Specific Meeting Advancing HR Excellence in Life Sciences